Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis.

Hyun Ho JoSeong Joon ChunJeong-Ju YooMin Hee LeeSang Gyune KimYoung Seok Kim

Published in: Journal of liver cancer (2020)

JX-594 is a modified oncolytic poxvirus designed to selectively replicate in and destroy cancer cells. In a pilot study, JX-594 injection followed by sorafenib was well-tolerated in three patients and associated with objective tumor responses. In this study, we report a case in which a patient with advanced hepatocellular carcinoma and portal vein thrombosis was treated with a combination of JX-594 and sorafenib.

Keyphrases

end stage renal disease
newly diagnosed
case report
pulmonary embolism
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes